Brokerages expect REDHILL BIOPHAR/S (NASDAQ:RDHL) to post earnings per share of ($0.39) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for REDHILL BIOPHAR/S’s earnings, with the highest EPS estimate coming in at ($0.38) and the lowest estimate coming in at ($0.40). REDHILL BIOPHAR/S reported earnings of ($0.50) per share during the same quarter last year, which suggests a positive year over year growth rate of 22%. The firm is expected to announce its next earnings results on Thursday, February 28th.
According to Zacks, analysts expect that REDHILL BIOPHAR/S will report full-year earnings of ($1.74) per share for the current year, with EPS estimates ranging from ($1.80) to ($1.67). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.41) per share, with EPS estimates ranging from ($1.80) to ($1.10). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that cover REDHILL BIOPHAR/S.
REDHILL BIOPHAR/S (NASDAQ:RDHL) last announced its earnings results on Tuesday, November 13th. The biotechnology company reported ($0.40) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.40). The company had revenue of $2.21 million during the quarter, compared to the consensus estimate of $2.54 million. REDHILL BIOPHAR/S had a negative net margin of 461.55% and a negative return on equity of 112.99%.
Several analysts have recently commented on the stock. Zacks Investment Research downgraded shares of REDHILL BIOPHAR/S from a “buy” rating to a “hold” rating in a report on Tuesday, November 6th. ValuEngine downgraded shares of REDHILL BIOPHAR/S from a “hold” rating to a “sell” rating in a report on Thursday, October 11th. Finally, HC Wainwright set a $36.00 target price on shares of REDHILL BIOPHAR/S and gave the company a “buy” rating in a report on Wednesday. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $20.81.
Shares of RDHL stock traded down $0.19 on Friday, hitting $7.90. The stock had a trading volume of 112,638 shares, compared to its average volume of 91,591. The company has a market cap of $177.20 million, a P/E ratio of -3.04 and a beta of 0.84. REDHILL BIOPHAR/S has a 12-month low of $4.30 and a 12-month high of $11.49.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Disciplined Growth Investors Inc. MN bought a new position in REDHILL BIOPHAR/S during the third quarter valued at about $295,000. Clear Harbor Asset Management LLC bought a new position in REDHILL BIOPHAR/S during the third quarter valued at about $323,000. JPMorgan Chase & Co. grew its position in REDHILL BIOPHAR/S by 61.4% during the third quarter. JPMorgan Chase & Co. now owns 73,878 shares of the biotechnology company’s stock valued at $652,000 after buying an additional 28,102 shares during the period. ARK Investment Management LLC grew its position in REDHILL BIOPHAR/S by 8.6% during the second quarter. ARK Investment Management LLC now owns 112,648 shares of the biotechnology company’s stock valued at $961,000 after buying an additional 8,894 shares during the period. Finally, Renaissance Technologies LLC bought a new position in REDHILL BIOPHAR/S during the third quarter valued at about $1,226,000. Institutional investors own 22.83% of the company’s stock.
REDHILL BIOPHAR/S Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs.
Recommended Story: Candlestick
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.